Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 13/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 13/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 13/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 13/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 13/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 13/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8819332 | 0.92 | PSEN1 (0.54) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9265915 | 0.91 | PSEN1 (0.51) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9268486 | 0.91 | PSEN1 (0.52) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9266846 | 0.91 | PSEN1 (0.53) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9265917 | 0.91 | PSEN1 (0.44) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9263538 | 0.91 | ROCK2 (0.60) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9263526 | 0.89 | PSEN1 (0.49) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9263078 | 0.89 | PSEN1 (0.49) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9268480 | 0.89 | PSEN1 (0.48) | ROCK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9268576 | 0.89 | PSEN1 (0.49) | ROCK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | ROCK2 4864/4885PSEN1 9/4885PSEN2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.